For the Inventor, By the Inventor

Enter assignee name

Procell Therapeutics Inc.

USPTO Granted Patents = 10

% Expired Patents = 50.0

EPO Patents = 5

Trademarks = 2

Forward Citations = 28

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Daewoong Jo (4 out of 4 patents)

Dae Woong Jo (3 out of 3 patents)

Thi Thuy Nga Do (3 out of 3 patents)

4. Minh Tam Duong (3 out of 3 patents)

5. Jin Sook Kim (3 out of 3 patents)

6. Kang Jin Lee (3 out of 3 patents)

7. Byung Kyu Lee (3 out of 3 patents)

8. Ki Deok Shin (2 out of 2 patents)

9. Sunny Lim (2 out of 2 patents)

10. Kyung Mi Park (2 out of 2 patents)

11. Jung Hee Lim (2 out of 2 patents)

12. Thi Lan Phuong Do (2 out of 2 patents)

13. Jung-Hee Lim (2 out of 2 patents)

14. Kisuk Park (2 out of 2 patents)

15. Jong Rae Kim (2 out of 2 patents)

10 patents: Sort by Forward Citations

1. 10300118 - Cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof (2019-05-28),

2. 9694087 - Development of novel macromolecule transduction domain with improved cell permeability and method for using same (2017-07-04),

3. 9259481 - Development of novel macromolecule transduction domain with improved cell permeability and method for using same (2016-02-16),

4. 9040477 - Macromolecule transduction domains and methods for identification and uses thereof (2015-05-26),

5. 8629097 - Macromolecule transduction domains and methods for identification and uses thereof (2014-01-14),

6. 8586544 - Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component (2013-11-19),

7. 8470971 - Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient (2013-06-25),

8. 8450279 - Cell permeable Nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same (2013-05-28),

9. 8445443 - Cell permeable p18 recombinant proteins, polynucleotides encoding the same, and anticancer composition comprising the same (2013-05-21),

10. 8158415 - Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells (2012-04-17),

Company Overview

Procell Therapeutics Inc. is a biotechnology company based in South Korea, focused on developing innovative therapeutic solutions. The organization specializes in advanced cellular and molecular therapies, aiming to address unmet medical needs in various disease areas. Procell Therapeutics leverages cutting-edge research in regenerative medicine and gene therapy, striving to enhance patient outcomes through its proprietary technologies and collaborative research initiatives. Its commitment to scientific excellence positions it as a key player in the global biotech landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

10 Patents

#33 in

#1,090 in South Korea

#56,047 in the World

Procell Therapeutics Inc.

Forward Citations = 28

24 inventors:

Daewoong Jo (4 out of 4 patents)

Dae Woong Jo (3 out of 3 patents)

Thi Thuy Nga Do (3 out of 3 patents)

4. Minh Tam Duong (3 out of 3 patents)

5. Jin Sook Kim (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Procell Therapeutics Inc.. Retrieved from https://idiyas.com/company/procell-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…